title: Dose-finding study of 5'-deoxy-5-fluorouridine in combination with fixed doses of cisplatin and L-folinic acid for the treatment of advanced or recurrent squamous cell carcinoma of the head and neck.
abstract: In order to assess the maximum tolerated dose of 5'-deoxy-5-fluorouridine (5dFUR) combined with a cisplatin (20 mg/m2 i.v.) and L-folinic acid (100 mg/m2 i.v.), 5-day schedule 19 consecutive chemotherapy-naive patients affected by advanced or recurrent carcinoma of the head and neck were entered in this phase I trial. Doses of 5dFUR were escalated from a starting level of 2,000 mg/m2/day up to 3,000 and 5,000 mg/m2/day. At the latter step the dose-limiting acute toxicities were stomatitis and diarrhea, which were of WHO grade 3-4 and occurred in 3 and 1 out of 4 evaluated patients, respectively. Other grade 3 acute toxicities were leukopenia, anemia, renal impairment, and neurologic symptoms, observed in 1 patient each. Furthermore, one possibly treatment-related death was registered among patients entered in the highest dose level. Eleven out of 19 patients (58%; 95% CI:34-80%) showed a complete (2 cases) or partial (9 cases) response to this treatment, regardless of the 5dFUR dosage employed. From our results we may define the maximum tolerated dose of 5dFUR to be associated with cisplatin and L-folin acid used in this trial as 3,000 mg/m2/day x 5 days. Assessment of the real activity of this combination chemotherapy deserves further studies.
authors.affiliation: Division of Medical Oncology A, National Cancer Institute, Milan, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Comella
authors.forename: M
authors.initials: M
authors.lastname: Biglietto
authors.forename: M
authors.initials: M
authors.lastname: Della Vittoria Scarpati
authors.forename: C G
authors.initials: CG
authors.lastname: Stampino
authors.forename: A
authors.initials: A
authors.lastname: Pandolfi
authors.forename: G
authors.initials: G
authors.lastname: Palmieri
authors.forename: G
authors.initials: G
authors.lastname: Carteni
authors.forename: G
authors.initials: G
authors.lastname: Catalano
authors.forename: G
authors.initials: G
authors.lastname: Comella
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003967:Diarrhea / Q000139:chemically induced; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage / Q000009:adverse effects; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology; D013280:Stomatitis / Q000139:chemically induced
chemical_list: D005467:Floxuridine; D002945:Cisplatin; D002955:Leucovorin; C025034:doxifluridine